S2k Guideline for the Treatment of Hidradenitis Suppurativa / Acne Inversa – Short Version

    May 2024 in “ JDDG Journal der Deutschen Dermatologischen Gesellschaft ”
    Christos C. Zouboulis, Falk G. Bechara, Klaus Fritz, Matthias Goebeler, Frank H. Hetzer, Elke Just, Natalia Kirsten, Georgios Kokolakis, Hjalmar Kurzen, Georgios Nikolakis, Andreas Pinter, Maurizio Podda, Kerstin Rosinski, Sylke Schneider‐Burrus, Klaus‐M. Taube, Thomas Volz, Thomas Winkler, Anna Kristandt, Dagmar Presser, Viktor A. Zouboulis
    Studysummary This guideline outlines therapies for hidradenitis suppurativa/acne inversa, noting that oral tetracyclines, clindamycin, and surgical options are important for treatment, with adalimumab, secukinumab, and bimekizumab also approved.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The S2k guideline for hidradenitis suppurativa/acne inversa (HS/AI) provides a framework for selecting appropriate therapies for this chronic, inflammatory skin disease affecting hair follicles. With a prevalence of 0.3% in Germany and often diagnosed after a significant delay, HS/AI significantly impacts quality of life. The guideline emphasizes the importance of using validated tools like the International Hidradenitis Suppurativa Severity Scoring System (IHS4) for classification and treatment decisions. Treatments include oral tetracyclines, intravenous clindamycin, and subcutaneous biologics like adalimumab, secukinumab, and bimekizumab. Surgical options are available for non-inflammatory forms, and combining drug and surgical treatments is recommended for a holistic approach.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results